Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 19:105:adv42794.
doi: 10.2340/actadv.v105.42794.

Determinants of Quality of Life in Patients with Atopic Dermatitis and Psoriasis: A Multivariate Approach

Carsten Spitzer  1 , Ines Buchholz  2 , Laura Lübke  3 , Clara Wülfing  4 , Katharina Meier  5 , Georgios Kokolakis  5 , Dennis Niebel  6 , Caroline Mann  7 , Ante Karoglan  8 , Steffen Emmert  9 , Alexander Thiem  9
Affiliations

Determinants of Quality of Life in Patients with Atopic Dermatitis and Psoriasis: A Multivariate Approach

Carsten Spitzer et al. Acta Derm Venereol. .

Abstract

Health-related quality of life (HRQoL) is reduced in atopic dermatitis and psoriasis. Several factors impact HRQoL including sociodemographic and skin disease-related characteristics, health behaviours, cardiometabolic comorbidities, and psychological conditions. However, their differential and unique effects on HRQoL are not well studied. In this cross-sectional online survey, adult patients with atopic dermatitis (n = 155) or psoriasis (n = 246) provided data on features of their respective skin diseases, health behaviours, and cardiometabolic comorbidities. Validated self-report measures assessed HRQoL, psychopathology (Patient Health Questionnaire-4), and stress (Perceived Stress Scale). Linear regression analyses were used to determine key predictors of HRQoL. In atopic dermatitis, linear regression analyses revealed that self-rated disease severity (Patient-Oriented Eczema Measure), anxiety, and stress were significant predictors of the Dermatology Life Quality Index (DLQI), explaining 59% of the variance. In psoriasis, disease severity (Psoriasis Symptoms and Signs Diary) and depression significantly predicted DLQI, with an explained variance of 57%. Health behaviours and cardiometabolic comorbidities did not impact DLQI scores. While skin disease severity is the most important determinant of HRQoL, stress and anxiety are important in atopic dermatitis, whereas depression is relevant in psoriasis. These findings hold implications for both clinical practice and research.

PubMed Disclaimer

Conflict of interest statement

IB is member of the EuroQol Group Association. CW has received consultant’s honoraria from Almirall. KM has received honoraria and travel support from AbbVie, Amgen, Almirall, Astra Zeneca, Biogen, Bristol-Myers Squibb, Lilly, Janssen, UCB Pharm, Leo Pharma, Novartis Pharma, and Takeda Phrmaceutical. GK has been a speaker and/or advisory board member for honoraria from AbbVie, Abbott, Actelion Pharmaceuticals, Amgen, Basilea Pharmaceutica, Bayer, Biogen IDEC, Boehringer, Bristol Myers Squibb, Celgene, Hexal, Janssen-Cilag, LEO Pharma, Lilly, MSD, Mylan, Novartis, Parexel, Pfizer, Sanofi-Aventis, STADA, Takeda, and UCB. DN reports financial support (speaker’s honoraria, advisory boards, travel expense reimbursements or grants) outside the submitted work from Abbvie, Almirall, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers-Squib, GlaxoSmithKline, Incyte, Janssen-Cilag, Kyowa Kirin, LEO Pharma, Lilly, L’Oreal/CeraVe, MSD, Novartis, Pfizer, Regeneron and UCB Pharma. CM has received honoraria or travel support from Abbvie, Almirall, Janssen, Novartis, Loréal, UCB, Apogee, Pfizer and UNEV and research support from Almirall, outside the scope of the submitted work. AK has received honoraria and/or travel support from Actelion Pharmaceuticals, AbbVie, Almirall, Amgen, Biofrontera, Bristol-Myers Squibb, Celgene, Delcath Systems, Eucerin, Jansen, La Roche Posay, Lilly, Medac, Novartis, Roche, Roxall, and UCB. SE has received honoraria or travel support from Abbvie, Almirall, Amgen, Bristol-Meyers Squibb, Cinogy, Galderma, Janssen, LEO, Malinckrodt, Mayne Genzyme Corporation, Merck Sharp & Dohme, Novartis, Oncobeta, Pierre-Fabre, Pfizer, RheaCell, Sanofi, SolGel, SUN Pharma, Teion, and UCB. AT has received honoraria and/ or travel support from AbbVie, Almirall, Boehringer Ingelheim, Bristol-Meyers Squibb, Galderma, GlaxoSmithKline, Janssen, Kyowa Kirin, LEO, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Pierre Fabre, Recordati Rare Diseases, Sanofi, and UCB, and research support from Cinogy, outside the scope of the submitted work. The other authors declare no conflicts of interest.

References

    1. Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM; Global Psoriasis Atlas . National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ 2020; 369: m1590. 10.1136/bmj.m1590 - DOI - PMC - PubMed
    1. Raimondo A, Lembo S. Atopic dermatitis: epidemiology and clinical phenotypes. Dermatol Pract Concept 2021; 11: e2021146. 10.5826/dpc.1104a146 - DOI - PMC - PubMed
    1. Cortés H, Rojas-Márquez M, Del Prado-Audelo ML, Reyes-Hernández OD, González-Del Carmen M, Leyva-Gómez G. Alterations in mental health and quality of life in patients with skin disorders: a narrative review. Int J Dermatol 2022; 61: 783–791. 10.1111/ijd.15852 - DOI - PubMed
    1. Fasseeh AN, Elezbawy B, Korra N, Tannira M, Dalle H, Aderian S, et al. Burden of atopic dermatitis in adults and adolescents: a systematic literature review. Dermatol Ther 2022; 12: 2653–2668. 10.1007/s13555-022-00819-6 - DOI - PMC - PubMed
    1. Obradors M, Blanch C, Comellas M, Figueras M, Lizan L. Health-related quality of life in patients with Psoriasis: a systematic review of the European literature. Qual Life Res 2016; 25: 2739–2754. 10.1007/s11136-016-1321-7 - DOI - PubMed

MeSH terms

LinkOut - more resources